AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02348710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise OE workbook
Description: The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
Study NCT02348710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet workbook
Description: The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
Study NCT00933465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imodium (Loperamide Hydrochloride) syrup
Description: syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most.
Study NCT00933465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imodium (Loperamide hydrochloride) tablets
Description: tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most
Study NCT02478164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Study NCT03981081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
Study NCT03981081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
Study NCT03046199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
Study NCT03046199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordination
Description: Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
Study NCT01388075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: oral, 450 mg/day , 7 days
Study NCT04592965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and neuropsychological assessments
Description: The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
Study NCT04592965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induction of PH and associated bodily states
Description: Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
Study NCT04592965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting-state fMRI acquisition
Description: Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
Study NCT04592965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of PH and associated bodily states (MRI)
Description: Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
Study NCT04471753 — intervention group
Intervention type: BEHAVIORAL
Intervention: Coma Recovery Scale-Revised
Description: Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
Study NCT04298996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: taking saliva samples to determine oxidative stress markers TAS and TOS
Study NCT01230489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MediHoney
Description: In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
Study NCT00355251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/Atorvastatin 80 mg
Description: Atorvastatin 40 mg/80 mg
Study NCT03629405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C - pH 4 Cosmetic Product WO 3741
Description: Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
Study NCT03629405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D - pH 5.8 Cosmetic Product WO 4081-1
Description: Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
Study NCT03802331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495,
Description: single oral doses
Study NCT04442464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral Lens
Description: 15.0 mm diagnostic spherical rigid contact lens
Study NCT04394039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public space exposure
Description: landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
Study NCT03215199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NAPT
Description: Web-based depression and distress monitoring application
Study NCT02138903 — intervention group
Intervention type: OTHER
Intervention: trans thoracic echocardiography
Study NCT01016327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-1116354
Description: Oral daily administration for 7 consecutive days every 14 days
Study NCT01331993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
Study NCT02942485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: P/r suppositories
Study NCT02942485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: P/o tablets
Study NCT00687674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg orally Days 1, 8, 15, 22 of 28 day cycle
Study NCT00687674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
Study NCT00687674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
Study NCT00663754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dissonance-based eating disorder prevention program
Description: Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
Study NCT01331993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
Study NCT01092325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1020
Description: Intravenous infusion of one of 3 active dosages of CXL-1020
Study NCT01331993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marketed enteric-coated naproxen formulation
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
Study NCT01092325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1020
Description: Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
Study NCT01092325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CXL-1020 Cohort 1
Description: A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
Study NCT01092325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CXL-1020 Cohort 2
Description: A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
Study NCT04519073 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V-306 candidate vaccine
Description: Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker.
Study NCT04519073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-306 candidate vaccine
Description: Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker.
Study NCT03296501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
Description: 3 injections of ADRC: 1 intraspinal and 2 intrathecal
Study NCT00490841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herculink Elite Renal Stent System
Description: This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
Study NCT05237323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil 2 g per day
Description: mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
Study NCT05237323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine of 150 [75; 150] mg per day
Description: azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
Study NCT02289703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg
Description: Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
Study NCT01236443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: 3 mg/m2 IV
Study NCT03051542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study NCT01188694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotherapy plus Methylene Blue, USP
Description: This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
Study NCT01188694 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy plus Placebo
Description: This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
Study NCT01188694 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Psychotherapy
Description: Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
Study NCT03893552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure
Description: Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
Study NCT02016625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Study NCT01092325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL-1020 Dose for Echo Cohort A
Description: A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
Study NCT01092325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL-1020 Doses for Echo Cohort B
Description: A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
Study NCT04518397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theatre
Description: 6-week participatory arts culturally-informed theatre program
Study NCT00430586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A, free of complexing proteins
Description: Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
Study NCT02016625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study NCT02016625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT00593307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high GI
Description: high GI and high carb breakfast
Study NCT00593307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI
Description: low GI, high carb breakfast
Study NCT00593307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI Low Carb
Description: low GI low carb breakfast
Study NCT00593307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Low carb
Description: high GI low carb breakfast
Study NCT00685243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: Fraxel and pulsed dye laser
Study NCT03160833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: oral administrative
Study NCT03459664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECOVER
Description: For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment.
Study NCT03459664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help.
Study NCT00830973 — intervention group
Intervention type: OTHER
Intervention: Poor Metabolism Status Follow Up Therapy Considerations
Description: If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
Study NCT00830973 — intervention group
Intervention type: OTHER
Intervention: CYP2D6 Inhibiting Drugs
Description: If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
Study NCT03209843 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous recanalization of chronic total occlusion
Description: Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
Study NCT01289483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol
Description: After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
Study NCT02819284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 0.25% Ophthalmic Suspension
Study NCT02819284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 0.25% Ophthalmic Suspension
Study NCT03345693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoTrack Therapy
Description: A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
Study NCT04695769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin
Description: Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
Study NCT04695769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
Description: Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
Study NCT03057821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% hydrogen peroxide
Description: The treatment group will also undergo skin preparation with 3% hydrogen peroxide.